Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.8667.5337
Address
Suite 4.01 65 Epping Road Macquarie Park, New South Wales (NSW) 2113
Description
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company was founded on July 11, 2017, and is headquartered in Brisbane, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.45 - 2.72
Trade Value (12mth)
AU$21,248.00
1 week
-2.78%
1 month
10.53%
YTD
0.48%
1 year
25.75%
All time high
4.20
EPS 3 yr Growth
-71.70%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-46.50%
ROIC
-21.20%
Interest Coverage
-112.90
Quick Ratio
6.40
Shares on Issue (Fully Dilluted)
85m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
28 August 24 |
Appendix 4E & Annual Report to 30 June 2024
×
Appendix 4E & Annual Report to 30 June 2024 |
28 August 24 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
30 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 July 24 |
First Responder Device Unveiled
×
First Responder Device Unveiled |
08 July 24 |
Stage 3 Recuitment Achieved & FDA Engagement Underway
×
Stage 3 Recuitment Achieved & FDA Engagement Underway |
24 June 24 |
Pilot Production Line Established & $1.25m Grant Received
×
Pilot Production Line Established & $1.25m Grant Received |
27 May 24 |
Trial data confirms early ischaemia detection capabilities
×
Trial data confirms early ischaemia detection capabilities |
26 April 24 |
Notification of cessation of securities - EMV
×
Notification of cessation of securities - EMV |
24 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
27 March 24 |
Stage 2 Insights Confirm Diagnostic & Clinical Viability
×
Stage 2 Insights Confirm Diagnostic & Clinical Viability |
13 March 24 |
ASA Milestone Achieved for $0.6m Grant Payment
×
ASA Milestone Achieved for $0.6m Grant Payment |
07 March 24 |
Board Changes
×
Board Changes |
07 March 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
07 March 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
01 March 24 |
Application for quotation of securities - EMV
×
Application for quotation of securities - EMV |
01 March 24 |
Application for quotation of securities - EMV
×
Application for quotation of securities - EMV |
01 March 24 |
Notification of cessation of securities - EMV
×
Notification of cessation of securities - EMV |
01 March 24 |
Cleansing Notice
×
Cleansing Notice |
01 March 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
29 February 24 |
Strategic A$15.28M Investment from Keysight Technologies
×
Strategic A$15.28M Investment from Keysight Technologies |
29 February 24 |
Proposed issue of securities - EMV
×
Proposed issue of securities - EMV |
29 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
29 February 24 |
CEO Half Yearly Update
×
CEO Half Yearly Update |
31 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 December 23 |
EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved
×
EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.